US · Healthcare · Biotechnology
EPS came in at -0.28 against a street estimate of -0.18 — a miss of 55.6%.
Analysts rate Achieve Life Sciences Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $14.15.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 7.40% |
| TPG GP A, LLC | 6.68% |
| venBio Partners LLC | 5.75% |
| Logos Global Management LP | 5.27% |
| BlackRock Inc | 5.12% |
| Franklin Templeton Inc | 4.81% |
| Paradigm Biocapital Advisors LP | 4.81% |
| Vanguard Capital Management, LLC | 4.02% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Achieve Life Sciences appointed Benjamin Halladay as Chief Financial Officer and principal financial officer, effective October 5, | 2026-10-01 |
| Company announcement · Q3 2026 ACHIEVE LIFE SCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company established an At-The-Market (ATM) offering program on August 14, 2026 • Maximu | 2026-08-14 |
| Quarterly report · Q2 2026 ACHIEVE LIFE SCIENCES, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $47.96 million in cash + $139.35 million in marketable securi | 2026-08-11 |
| Results announced · Q3 2026 ACHIEVE LIFE SCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $187.3 million (June 3 | 2026-08-11 |
| Charter / bylaws change · Q3 2026 ACHIEVE LIFE SCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held July 2, 2026 • Nine board directors elected with st | 2026-07-06 |
| Proxy statement · Q2 2026 PROXY STATEMENT SUMMARY FOR ACHIEVE LIFE SCIENCES, INC. WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Elect nine directors to serve until next ann | 2026-06-08 |
| Board / officer change · Q2 2026 ACHIEVE LIFE SCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • Two new board directors appointed effective May 29, 2026: Jeff Farrow and Reid Waldman, | 2026-06-02 |
| Quarterly report · Q1 2026 ACHIEVE LIFE SCIENCES, INC. — FORM 10-Q SUMMARY (Q1 2026) --- HEADLINE NUMBERS • Cash Position: $28.1 million in cash and cash equivalents as of Ma | 2026-05-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Achieve Life Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.